From the Literature

Published: Aug 2001

Holcomb J, Mattox KL, Schreiber MA, Martinowitz U

Recombinant activated factor VII for adjunctive hemorrhage control in trauma - Discussion.
J Trauma 2001;51(3):438-439.

#

NATA REVIEW:
Comments were given by the authors on the paper by Martinowitz et al., mentioning that the...
REVIEW by:
M. Aldouri

Published: Aug 2001

Chuansumrit A, Sri-Udomporn N, Srimuninnimit V, Juntarukha R

A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
Haemophilia 2001;7(5):532-534.

#

NATA REVIEW:
A single dose of rFVIIa (150-180 μg/kg) was used to treat five muscle/joint bleeds and...
REVIEW by:
M. Aldouri

Published: Aug 2001

Poon MC

Use of recombinant factor VIIa in hereditary bleeding disorders.
Curr Opin Hematol 2001;8(5):312-318.

#

NATA REVIEW:
This is another excellent review of the mechanism of action, indications, and various doses...
REVIEW by:
M. Aldouri

Published: Aug 2001

Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures.
Haemophilia 2001;7(5):517-522.

#

NATA REVIEW:
This is a case report of a child with severe hemophilia B and high titer factor IX inhibitor...
REVIEW by:
M. Aldouri

Published: Aug 2001

Martinowitz U, Kenet G, Segal E, et al.

Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
J Trauma 2001;51(3):431-438.

#

NATA REVIEW:
This is a relatively new area for using rFVIIa, which is to treat uncontrolled haemorrhage...
REVIEW by:
M. Aldouri

Published: Aug 2001

Kheirabadi BS, Pearson R, Rudnicka K, et al.

Development of an animal model for assessment of the hemostatic efficacy of fibrin sealant in vascular surgery.
J Surg Res 2001;100(1):84-92.

#

NATA REVIEW:
Having a sound and reproducible animal model to test the value of an existing therapy beyond...
REVIEW by:
R. K. Spence

Published: Jul 2001

Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D

Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
Bone Marrow Transplant 2001;28(4):405-407.

#

NATA REVIEW:
This is a report on off-label extended use of rFVIIa in managing pulmonary, vesical and GI...
REVIEW by:
M. Aldouri

Published: Jul 2001

Jurlander B, Thim L, Klausen NK, et al.

Recombinant activated factor VII (RFVIIa): Characterization, manufacturing, and clinical development.
Semin Thromb Hemostasis 2001;27(4):373-383.

#

NATA REVIEW:
A good overall review on the characterization, mechanism of action, and preclinical and...
REVIEW by:
M. Aldouri

Published: Jul 2001

Erhardtsen E, Nilsson P, Johannessen M, Thomsen MS

Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.
J Clin Pharmacol 2001;41(8):880-885.

#

NATA REVIEW:
This is a double-blind placebo controlled dose escalation trial evaluating efficacy and safety...
REVIEW by:
M. Aldouri; J. Ingerslev

Published: Mar 2001

Barsoum WK, Klika AK, Murray TG, Higuera C, Lee HH, Krebs VE

Prospective randomized evaluation of the need for blood transfusion during primary total hip arthroplasty with use of a bipolar sealer.
J Bone Joint Surg Am 2011;93(6):513-518.

#

NATA REVIEW:
This prospective randomized study tested the hemostatic efficacy of a bipolar sealer used during total hip...
REVIEW by:
E. Bisbe

Pages